Floatz logo

Vcn-01

Locally Advanced Solid Tumors

Theriva Biologics SLPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Locally Advanced Solid Tumors cohort.

Asset / SponsorPhaseRating
ANTI-GLOBO H MONOCLONAL ANTIBODY OBI-888
OBI Pharma, Inc
Phase 1/2CC
Repotrectinib
Turning Point Therapeutics, Inc.
Phase 1/2CC
[131]i-iaza
University of Alberta
Phase 1/2CC
Entrectinib
Hoffmann-La Roche
Phase 1CC
Retifanlimab
Incyte Corporation
Phase 1CC

View all 9 →

Same molecule, other indications

Vcn-01 is also rated in:

pancreatic adenocarcinomaDormant
B
Indicative ·
58 / 100
View asset →
metastatic neoplasmDormant
B
Indicative ·
57 / 100
View asset →
ovarian serous adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →